These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28410588)

  • 1. Evidence synthesis to inform model-based cost-effectiveness evaluations of diagnostic tests: a methodological review of health technology assessments.
    Shinkins B; Yang Y; Abel L; Fanshawe TR
    BMC Med Res Methodol; 2017 Apr; 17(1):56. PubMed ID: 28410588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How is evidence on test performance synthesized for economic decision models of diagnostic tests? A systematic appraisal of Health Technology Assessments in the UK since 1997.
    Novielli N; Cooper NJ; Abrams KR; Sutton AJ
    Value Health; 2010 Dec; 13(8):952-7. PubMed ID: 21029247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems.
    Main C; Moxham T; Wyatt JC; Kay J; Anderson R; Stein K
    Health Technol Assess; 2010 Oct; 14(48):1-227. PubMed ID: 21034668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.
    Stevenson M; Pandor A; Martyn-St James M; Rafia R; Uttley L; Stevens J; Sanderson J; Wong R; Perkins GD; McMullan R; Dark P
    Health Technol Assess; 2016 Jun; 20(46):1-246. PubMed ID: 27355222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are adverse effects incorporated in economic models? An initial review of current practice.
    Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
    Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Decision Modelling in Economic Evaluations of Diagnostic Tests: An Appraisal and Review of Health Technology Assessments in the UK.
    Yang Y; Abel L; Buchanan J; Fanshawe T; Shinkins B
    Pharmacoecon Open; 2019 Sep; 3(3):281-291. PubMed ID: 30552651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath.
    Harnan SE; Tappenden P; Essat M; Gomersall T; Minton J; Wong R; Pavord I; Everard M; Lawson R
    Health Technol Assess; 2015 Oct; 19(82):1-330. PubMed ID: 26484874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests.
    Smith AF; Messenger M; Hall P; Hulme C
    Pharmacoeconomics; 2018 Jul; 36(7):823-835. PubMed ID: 29502176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
    Burch J; Hinde S; Palmer S; Beyer F; Minton J; Marson A; Wieshmann U; Woolacott N; Soares M
    Health Technol Assess; 2012; 16(34):1-157, iii-iv. PubMed ID: 22985954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
    Frampton GK; Jones J; Rose M; Payne L
    Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice Recommendations.
    Shinkins B; Allen AJ; Karichu J; Garrison LP; Monz BU
    Appl Health Econ Health Policy; 2024 Mar; 22(2):131-144. PubMed ID: 38316713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
    Taylor RS; Elston J
    Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer.
    Huxley N; Jones-Hughes T; Coelho H; Snowsill T; Cooper C; Meng Y; Hyde C; Mújica-Mota R
    Health Technol Assess; 2015 Jan; 19(2):v-xxv, 1-215. PubMed ID: 25586547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of near patient testing in primary care.
    Hobbs FD; Delaney BC; Fitzmaurice DA; Wilson S; Hyde CJ; Thorpe GH; Earl-Slater AS; Jowett S; Tobias RS
    Health Technol Assess; 1997; 1(5):i-iv, 1-229. PubMed ID: 9483154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.
    Nicholson A; Mahon J; Boland A; Beale S; Dwan K; Fleeman N; Hockenhull J; Dundar Y
    Health Technol Assess; 2015 Oct; 19(87):i-xxxi, 1-191. PubMed ID: 26507078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.
    Doble B; Tan M; Harris A; Lorgelly P
    Expert Rev Mol Diagn; 2015 Feb; 15(2):235-54. PubMed ID: 25142227
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.